CCWM
RXRX icon

Cassaday & Co Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Cassaday & Co Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.52K Hold
960
– – ﹤0.01% 985
2026
Q1 		$2.95K Buy
+960
New +$3.71K ﹤0.01% 1035

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cassaday & Co Wealth Management's RXRX Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 960 shares worth $3.52K. The position accounts for ﹤0.01% of the portfolio, ranked #985.

Cassaday & Co Wealth Management first reported a position in RXRX in Q1 2026 and has held it in 2 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Cassaday & Co Wealth Management held 960 shares of Recursion Pharmaceuticals worth $3.52K as of Q2 2026.
  • Cassaday & Co Wealth Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #985 holding.
  • Cassaday & Co Wealth Management first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.